Company: TXG
Filing Date: 2025-04-14
Form Type: DEF 14A
Source: 0001770787-25-000018
Chunk: 40

Company: 10x Genomics, Inc.
Filing Date: 2025-04-14
Form: DEF 14A
Chunk 40
---
     |                                                                                   |     |                   |     |                                                                                                                                                                                                                          |
|            |     | Clawback Policy:We maintain a clawback policy in line with SEC and Nasdaq rules which applies to each of our Named Executive Officers.                                                                                                        |     |                                                                                   |     |                   |     | No Excessive Perquisites:We do not generally offer perquisites or personal benefits to our executives.                                                                                                                   |
|            |     | Annual Say on Pay Vote:We conduct a Say on Pay vote annually.                                                                                                                                                                                 |     |                                                                                   |     |                   |     | No Unearned Dividends:We do not accrue or pay dividends on unearned or unvested equity awards.                                                                                                                           |
|            |     | Stockholder Outreach:We engage in stockholder outreach to solicit feedback and to discuss our business and compensation program throughout the year.                                                                                          |     |                                                                                   |     |                   |     | No Encouragement of Unnecessary or Excessive Risk Taking:Our compensation program aligns executive and shareholder interests, which reduces incentives for short-term risk taking.                                       |

#### 10X GENOMICS, INC.422025 PROXY STATEMENT
Say on Pay Vote Results and Shareholder Outreach Highlights

#### Results of Prior Say on Pay Vote
At our 2024 annual meeting of stockholders, we presented our stockholders with a proposal to approve on an advisory basis, the compensation of our named executive officers as disclosed in our 2024 proxy statement. Approximately 83% of the votes on this proposal were cast in 2024 in support of our 2023 executive compensation program.

#### Response to Say on Pay Vote
The compensation committee continues to be committed to consider the results of stockholder advisory votes on executive compensation when making decisions relating to our executive compensation programs and compensation for named executive officers, with the intent on making sure that the programs are beneficial to the creation of sustained long-term stockholder value.

Though our executive compensation programs have been widely supported, our management engaged with key stockholders to solicit on-going feedback on our programs. Significant outreach was conducted in 2024 and was led by our Chief People Officer. She was joined by a number of members of management, including our Chief Legal Officer, Chief Financial Officer, Vice President of Total Rewards, our Senior Director, Investor Relations and Strategic Finance and Senior Director, Corporate.

We contacted each of our top stockholders, representing over 48% of the Company’s outstanding shares of common stock. We ultimately spoke with five stock